Clostridioides difficile Infection (CDI) Surveillance

What to know

  • The Clostridioides difficile infection (CDI) Surveillance Program collects data for describing incidence and trends of these infections.
  • Public health professionals and healthcare providers can use these data to further public health research and improve health outcomes.

Overview

Aims

As part of CDC's Emerging Infections Program (EIP) Healthcare-Associated Infections – Community Interface Activity (HAIC), the Clostridioides difficile infection (CDI) Surveillance Program identifies and monitors:

  • CDI incidence and burden in communities and healthcare settings.
  • Molecular and microbiologic characteristics of strains causing disease.
  • Trends in disease over time, including changes in strain prevalence.

Process

To collect this information, trained professionals conduct active population- and laboratory-based surveillance in 10 EIP sites. CDC and EIP staff clean, analyze, and disseminate the data through annual reports and peer-reviewed publications.

Purpose

Public health and healthcare professionals can use these data to further research such as:

  • Identifying risk factors for CDI.
  • Identifying populations to prioritize for vaccines and other prevention measures.
  • Monitoring effectiveness of prevention strategies.

Highlights

Trends in age, sex, and race/ethnicity

In 2023, the incidence of CDI increased with age, was higher in women than in men, and highest in persons who were Native Hawaiian/Pacific Islander or among White people, compared to people of other racial/ethnic groups. 1

What the data shows

  • There were 117.2 cases per 100,000 people in EIP sites in 2023.
  • Underlying medical conditions were common among people who were CDI cases.
  • 63% of people who were CDI cases used antibiotics in the prior 12 weeks.1

Explore the data

Access and create data visualizations

HAICViz is an interactive data dashboard that provides information included in the reports below as well as case rates and deaths over time.

Annual reports

Publications using CDI Surveillance Program data

About the data

EIP sites
Area under Surveillance

California

San Francisco County

Colorado

Adams, Arapahoe, Denver, Douglas and Jefferson Counties

Connecticut

Naugatuck Valley and South Central Connecticut Planning Regions

Georgia

Clayton, Cobb, DeKalb, Douglas, Fulton, Gwinnett, Newton and Rockdale Counties

Maryland

Caroline, Cecil, Dorchester, Frederick, Kent, Somerset, Talbot, Queen Anne’s, Washington, Wicomico and Worcester Counties

Minnesota

Benton, Morrison, Olmsted, Stearns and Todd Counties

New Mexico

Bernalillo County

New York

Monroe County

Oregon

Klamath County

Tennessee

Davidson County

Incident case

When the following criteria are met for a patient who lives in the surveillance area:

  • A patient with a positive C. difficile toxin assay or a positive C. difficile molecular assay (e.g., PCR) performed on a stool specimen, without a positive specimen in the prior 8 weeks.
    • Patient must be at least 1 year old.
    • For surveillance purposes, an individual may be classified and captured as a new incident case if 8 consecutive weeks have elapsed since their last C. difficile-positive test.

Recurrent episodes

  • Patients with a positive C. difficile stool specimen between 2 and 8 weeks of the last positive specimen.

Duplicate episodes

  • Patients with a positive C. difficile stool specimen less than 2 weeks since the last positive specimen.

EIP site staff identify cases based on reports of positive C. difficile toxin assays or C. difficile nucleic acid amplification assays from clinical, reference and commercial laboratories serving residents of the surveillance areas.

EIP site staff record information on additional positive specimens from the same patient to identify and track recurrent or duplicate episodes, as well as new cases.

To determine epidemiologic class, EIP site staff perform a brief medical record review of all* incident CDI cases to collect the following data:

  • Basic demographic characteristics.
  • Location of stool collection.
  • Healthcare exposures.

EIP site staff do not review records of recurrent or duplicate episodes.

*In Colorado and Georgia (the EIP sites with the largest surveillance populations), EIP site staff review a random sample of incident cases.

  1. Healthcare facility-onset (HCFO) if the positive stool specimen collected is either:
    1. Greater than three calendar days after hospital admission.
    2. In a resident of a long-term care facility.
  2. Community-onset healthcare facility-associated (CO-HCFA) if the positive stool specimen collected is:
    1. Either in an outpatient setting or within 3 calendar days after hospital admission.
    2. In a person with documented overnight stay in a healthcare facility (i.e., hospitalization or long-term care facility stay) in the 12 weeks before stool specimen collection.
  3. Community–associated (CA) if positive stool specimen collected is:
    1. Either in an outpatient setting or within 3 calendar days after hospital admission.
    2. In a person with no documented overnight stay in a healthcare facility during the 12 weeks before the specimen collection.

A portion of cases subsequently undergo a comprehensive medical record review for clinical information and relevant risk factors.

Laboratory characterization

EIP site staff collect a convenience sample of stool specimens from incident CDI cases for whom case report forms have been completed. Stool specimens are sent to reference laboratories for culture. C. difficile isolates obtained from these cultures are sent to CDC for molecular typing and characterization.

Resources

Case report form for EIP surveillance staff

  1. Centers for Disease Control and Prevention. 2025. Emerging Infections Program, Healthcare-Associated Infections – Community Interface Surveillance Report, Clostridioides difficile infection (CDI), 2023. Available at: https://www.cdc.gov/healthcare-associated-infections/media/pdfs/2023-CDI-Report-508.pdf